Abstract
Aging is characterized by clonal expansion of myeloid-biased hematopoietic stem cells and by increased risk of myeloid malignancies. Exome sequencing of three elderly females with clonal hematopoiesis, demonstrated by X-inactivation analysis, identified somatic TET2 mutations. Recurrence testing identified TET2 mutations in 10 out of 182 individuals with X-inactivation skewing. TET2 mutations were specific to individuals with clonal hematopoiesis without hematological malignancies and were associated with alterations in DNA methylation.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Nuclear localization of TET2 requires β-catenin activation and correlates with favourable prognosis in colorectal cancer
Cell Death & Disease Open Access 24 August 2023
-
Recent advances in targeted therapies in acute myeloid leukemia
Journal of Hematology & Oncology Open Access 25 March 2023
-
Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment
Blood Cancer Journal Open Access 04 January 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout

Accession codes
References
Beerman, I., Maloney, W.J., Weissmann, I.L. & Rossi, D.J. Curr. Opin. Immunol. 22, 500–506 (2010).
Beerman, I. et al. Proc. Natl. Acad. Sci. USA 107, 5465–5470 (2010).
Busque, L. et al. Blood 88, 59 (1996).
Gale, R.E., Fielding, A.K., Harrison, C.N. & Linch, D.C. Br. J. Haematol. 98, 512–519 (1997).
Busque, L. & Gilliland, D.G. Leukemia 12, 128–135 (1998).
Delhommeau, F. et al. N. Engl. J. Med. 360, 2289–2301 (2009).
Moran-Crusio, K. et al. Cancer Cell 20, 11–24 (2011).
Quivoron, C. et al. Cancer Cell 20, 25–38 (2011).
Li, Z. et al. Blood 118, 4509–4518 (2011).
Ko, M. et al. Proc. Natl. Acad. Sci. USA 108, 14566–14571 (2011).
Tefferi, A. et al. Leukemia 23, 905–911 (2009).
Ko, M. et al. Nature 468, 839–843 (2010).
Figueroa, M.E. et al. Cancer Cell 18, 553–567 (2010).
Acknowledgements
We thank members of the Levine and Busque laboratories for helpful comments and discussion. This work was supported by a grant from the National Cancer Institute Physical Sciences Oncology Center (U54CA143798-01) to R.L.L. and A.M., by grant 1R01CA138234-01 to R.L.L. and by grants 1R01CA129831 and 1R01CA129831-03S1 to L.A.G. from the National Cancer Institute. A. Vasanthakumar is supported by a US National Institutes of Health F32 award. M.E.F. is supported by a Leukemia and Lymphoma Society Special Fellow award and a Doris Duke Charitable Foundation Clinical Scientist Development Award. O.A.-W. is an American Society of Hematology Basic Research Fellow. A.M. is a Burroughs Wellcome Clinical Translational Scholar and is also supported by the Sackler Center for Biomedical and Physical Sciences. R.L.L. is an Early Career Award Recipient of the Howard Hughes Medical Institute. R.L.L. and A.M. are funded by Leukemia and Lymphoma Society Scholar Awards. All subjects answered a medical questionnaire and gave informed consent. The study was approved by the Maisonneuve-Rosemont Hospital's Ethics Committee in 1998 and is reapproved yearly in accordance with institutional bylaws.
Author information
Authors and Affiliations
Contributions
L.B., J.P.P., O.A.-W. and R.L.L. designed the study. L.B., S.P., Z.H. and L.M. collected samples and provided genetic and clinical annotation. J.P.P., J.L., A. Vasanthakumar, A.H., M.H., N.S., P.K.B., C.E.M. and C.W.B. performed sequence analysis and validated mutations. M.E.F., A. Viale, A.M. and L.A.G. performed methylation analysis. M.G. performed statistical analysis. L.B., J.P.P., O.A.-W. and R.L.L. wrote the manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Methods, Supplementary Figures 1 and 2 and Supplementary Tables 1–4 (PDF 1427 kb)
Rights and permissions
About this article
Cite this article
Busque, L., Patel, J., Figueroa, M. et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 44, 1179–1181 (2012). https://doi.org/10.1038/ng.2413
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.2413
This article is cited by
-
Recent advances in targeted therapies in acute myeloid leukemia
Journal of Hematology & Oncology (2023)
-
Clonal haematopoiesis and dysregulation of the immune system
Nature Reviews Immunology (2023)
-
Nuclear localization of TET2 requires β-catenin activation and correlates with favourable prognosis in colorectal cancer
Cell Death & Disease (2023)
-
Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment
Blood Cancer Journal (2023)
-
Blockade of IL-6 signaling alleviates atherosclerosis in Tet2-deficient clonal hematopoiesis
Nature Cardiovascular Research (2023)